NEW ORLEANS, Nov. 16, 2010 (GLOBE NEWSWIRE) -- Protea Biosciences, Inc., a leading developer of technology for biomolecular analysis, announced today that the company has completed an expansion of its GLP Bioanalytical Laboratory, including the introduction of quantitative proteomics mass spectrometry services. The announcement was made today at the Annual Meeting of the American Association of Pharmaceutical Scientists (AAPS).
"By employing new mass spectrometry methods, we can realize the same specificity for protein and peptide therapeutics as we have for small molecules," stated Jason Breaux, Director of Protea's Bioanalytical Laboratory. "Our laboratory can achieve the same quantitative sensitivity that is achieved with current ELISA techniques, but can eliminate the need for antibodies and the attendant false positives and false negatives that are inherent with the ELISA method, thereby providing better data," he added.
Protea's Bioanalytical Laboratory offers method development, validation, and sample analysis services for both small and large molecules in a GLP environment. The company's laboratory expansion included the acquisition of new Watson LIMS and TrackWise software, and several mass spectrometers, including a second AB Sciex 5500QTRAP, two AB Sciex 4000's, and a Waters Synapt G2 HDMS QTOF.
Protea Biosciences, Inc. (www.proteabio.com) develops new bioanalytical technologies that enable the direct analysis of proteins, metabolites, and other biomolecules, and applies their technology to the development of new pharmaceuticals, products and services. Protea Biosciences is based in Morgantown, West Virginia.